Idogen

Be the first to follow this company

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection.

ShowingAll content types

Regulatory press release6/6/2023, 11:04 AM

Idogen's Board of Directors proposes that liquidation is not to be resolved at the Annual General Meeting on June 8.

Regulatory press release5/30/2023, 6:03 AM

Idogen working for a sale of its proprietary technology platform

Press release5/10/2023, 6:36 AM

Redeye: Idogen - Q1 2023 – In a tough situation

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release4/28/2023, 6:02 AM

Idogen in discussions about a reversed merger. The company intends to add an agenda item at the annual general meeting on June 8 for possible liquidation

Regulatory press release4/18/2023, 6:01 AM

Idogen is investigating reverse acquisitions to avoid risk of liquidation

Press release2/27/2023, 7:48 AM

Redeye: Idogen Q4 2022 - The future is contingent on funding

Regulatory press release2/24/2023, 11:04 AM

Idogen publishes interim report for 1 January - 31 December 2022

Press release2/7/2023, 7:22 AM

BioStock: Idogen one of ten companies selected for field-leading event

Press release1/31/2023, 12:17 PM

Idogen invited by GJCF to participate in their 3[rd] Summit for NMOSD Tolerization

Regulatory press release1/17/2023, 4:31 PM

Idogen announces outcome of rights issue

Press release1/9/2023, 7:03 AM

Last day for subscription of shares in Idogen's rights issue is Friday January 13, 2023

Press release12/12/2022, 7:14 AM

Idogen's first clinical trial, "Toler8", briefly described in Blood

Press release11/25/2022, 7:29 AM

BioStock: Idogen strengthens the Board with Jan Holgersson

Press release11/14/2022, 2:16 PM

Idogen's financial contribution from Horizon 2020 now finalizes with a publication

Regulatory press release11/8/2022, 5:01 PM

Idogen carries out a rights issue of approximately SEK 43.7 million

Regulatory press release11/1/2022, 6:16 PM

Agneta Edberg elected as new Chairman of Idogen due to changes to the Board of Directors

Press release10/17/2022, 6:03 AM

Idogen: EU to disburse the remaining MSEK 4.7 of the Horizon grant

Regulatory press release10/3/2022, 8:07 PM

Idogen sharpens focus on its IDO 8 program and lowers operating expenditure

Regulatory press release10/3/2022, 4:01 PM

Idogen announces outcome of exercise period for warrants of series TO 5

Press release9/27/2022, 7:51 AM

BioStock: Exciting times for Idogen's new Chairman of the Board

Forum discussions

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or...

10/17/2022, 8:11 AM

by Olivier A. de Goeij

0

Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.